RxDoctor Payments Data

Rifki Goldin Mertdogan, MD

Psychiatry · Morris, ILNPI 1346289980

Payments from drug & device makers

$10,756in general payments, 2019–2025

Across 572 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$759
  • Vanda Pharmaceuticals Inc.$739
  • Johnson & Johnson$684
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$10,728100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,756 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$49,372
Medicare patients
173
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole43$87,499
VraylarCariprazine Hcl32$56,338
CaplytaLumateperone Tosylate25$41,170
TrintellixVortioxetine Hydrobromide34$17,118
Aripiprazole179$13,982
Lurasidone Hcl40$13,145
Clomipramine Hcl22$9,255
Quetiapine Fumarate181$5,464
Pregabalin51$5,209
Desvenlafaxine Succinate ErDesvenlafaxine Succinate40$5,018
Methylphenidate ErMethylphenidate Hcl65$4,103
Bupropion XlBupropion Hcl168$3,925
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine129$3,720
Naltrexone Hcl17$3,502
Clonazepam440$3,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,347$87,49943 claims
AbbVieVraylar$1,464$56,33832 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$388$41,17025 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$759$17,11834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Morris

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →